CORPORATE PRESENTATION August 2020 Fortress Biotech FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration No. 333 - 226089 August 24, 2020

The issuer has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the SEC for the offering to which this communication relates . Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement, and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering . You may get these documents for free by visiting EDGAR on the SEC Web site at www . sec . gov . Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and prospectus if you request it by emailing info@fortressbiotech . com . 2

Forward Looking Statements This presentation may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , as amended . For such forward - looking statements, we claim the protection of the safe harbor for forward - looking statements contained in the Private Securities Litigation Reform Act of 1995 . As used below and throughout this presentation, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context . Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts . Forward - looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price . Factors that could cause actual results to differ materially from those currently anticipated include : risks related to our growth strategy ; risks relating to the results of research and development activities ; our ability to obtain, perform under and maintain financing and strategic agreements and relationships ; uncertainties relating to preclinical and clinical testing ; our dependence on third party suppliers ; our ability to attract, integrate, and retain key personnel ; the early stage of products under development ; our need for and continued access to additional funds ; government regulation ; patent and intellectual property matters ; competition ; as well as other risks described in our Securities and Exchange Commission filings . We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law . The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this presentation should be read as applying mutatis mutandis to every other instance of such information appearing herein . 3

Summary of Expected Offering Terms Security: 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Current Nasdaq Symbol: FBIOP Number of Preferred Shares Currently Outstanding: 2,693,806 Monthly Dividends: $0.1953125 Dividend Payment Dates: Monthly on the last calendar day of each month Liquidation Preference: $25.00 Maturity/Mandatory Redemption: None Optional Redemption: At the Company’s option any time on or after December 15, 2022 Use of Proceeds: General corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital. Potential Tax Treatment: Any portion of a distribution that exceeds our current and accumulated earnings and profits will first be applied to reduce a U.S. holder’s tax basis in the Series A Preferred Stock, but not below zero. Distributions in excess of our current and accumulated earnings and profits and in excess of a U.S. holder’s tax basis in its shares will be taxable as gain from the disposition of the Series A Preferred Stock. Joint Bookrunning Managers: The Benchmark Company ThinkEquity , a division of Fordham Financial Management, Inc. 4

5 The Opportunity ONE TWO THREE FOUR Valuation Dislocation Near - term Key Catalysts that will Create Value Opportunities Robust Pipeline with 25+ Development - stage Biotech Product Candidates 1 Solid Track Record of Execution FIVE Near - term Revenue Growth 1 Includes employees and product candidates in development at Fortress, at its majority - owned and majority - controlled partners.

Commercial Late Clinical Early Clinical Preclinical Targadox ® Cosibelimab MB - 102 ATVS - 001 Gene Therapy Ximino ® MB - 107 / MB - 207 CK - 101 AAV - ATP7A Gene Therapy Exelderm ® CAEL - 101 MB - 101 Anti - GITR Ceracade ® CUTX - 101 MB - 106 Anti - CAIX Luxamend ® CEVA - 101 MB - 103 CK - 103 IV Tramadol MB - 108 CEVA - 102 Triplex MB - 104 ConVax MB - 105 KRAS G12D ONCOlogues BAER - 101 Multiple Other ONCOlogues Fortress Biotech Programs* *Includes product candidates in development at Fortress, at its majority - owned and majority - controlled subsidiaries and at entit ies in which it holds minority ownership positions. 6 Dermatology Gene Therapy Oncology / Hematology Pain Rare Diseases Traumatic Brain Injury Vaccines CNS Disorders

Generating Cash Flow & Shareholder Value 7 Creating value in five ways Fortress Biotech

Dermatology Product Revenue Growth Expect to acquire 1 to 2 new products in 2020 Reaching >70% of market via top 5,000 prescribing dermatologists $3.6 $15.5 $23.4 $34.9 $21.4 2016 2017 2018 2019 1H 2020 $ in millions 331% GROWTH 51% GROWTH 49% GROWTH 50% GROWTH OVER 1H 2019 8

Identify Monetize Develop Strategy To build a pipeline of both development - stage / commercial - stage assets and leverage the most efficient course to move products forward with our partners. 9

Development Team Programs Secret Sauce How We Do It o 10+ Business Development Professionals o 30+ Manufacturing Professionals 1 o 25+ MDs and PhDs 1 o Current portfolio includes: 5 revenue - generating dermatology products o 25+ development - stage biotech product candidates 1 o Relatively de - risked assets o High value / need o Low acquisition cost o Known buyers 1 Includes employees and product candidates in development at Fortress, at its majority - owned and majority - controlled partners. Aim to increase the intrinsic value and decrease the overall risk of Fortress 10

Lindsay Rosenwald, MD Chairman, President, and CEO Michael S. Weiss Co - Vice Chairman of the Board, Strategic Development Eric K. Rowinsky, MD Co - Vice Chairman of the Board Robyn Hunter Chief Financial Officer George C. Avgerinos, PhD Senior Vice President, Operations Management Profiles 11

Top - tier Academic & Commercial Partners 12

o Upon FDA approval and other conditions 1 o $180 Million aggregate cash purchase; (est. $13.92/share) 1 ; FBIO 29% or eligible to receive ~$48M of the distribution net of fees o Potential additional payments pursuant to Contingent Value Rights; CVR payout of 10 - 20% of gross profits 2 o FBIO stands to realize ~$48M in addition to value of CVRs o Alexion purchased minority stock position in Caelum for $30M, with up to an additional $110M in funding due upon achievement of development milestones o Additionally, up to $500M payable to Caelum shareholders in connection with Alexion option exercise: • $150M upfront • Up to $350M in contingent approval / sales milestone payments o FBIO owns ~40% of Caelum and is eligible to receive ~43% of upfront and approval/sales milestone proceeds in event of Alexion exercise of contingent option Near - term Monetization Opportunities 1 subject to conditions described in Avenue public filings 2 Fortress to receive ~1/3 of CVR royalty if certain net sales thresholds are met Contingent Exclusive Acquisition Option Granted To Alexion (Jan. 2019) Contingent Acquisition By Cipla 13

Candidate* Indication Phase 1 Phase 2 Phase 3 Next Milestone Partnership % / Royalty † Potential Peak Sales Revenue^ IV Tramadol Moderate to moderately severe post - operative pain PDUFA action date of October 10, 2020 29% Avenue** 10 - 20% CVR Royalty on gross profits**** ~$790M MB - 107 & MB - 207 Gene Therapy XSCID (newly diagnosed) XSCID (previously transplanted) File IND for MB - 207 (previously transplanted patients) in 4Q 2020 25% Mustang 4.5% Royalty ~$200M CUTX - 101 Copper Histidinate Menkes disease Rolling NDA submission expected to start in 4Q 2020 and be completed in 1H 2021 79% Cyprium 4.5% Royalty ~$175M COSIBELIMAB Anti - PD - L1 mAb . Recurrent or metastatic cancers P1 Registration - enabling expansion cohorts ongoing; potential to support 1 or more BLA filings 21% Checkpoint 4.5% Royalty $300M - $500M (initial indication CSCC) CK - 101 Mut. - EGFR Inh . EGFR + NSCLC Initiate Registration Study 21% Checkpoint 4.5% Royalty $300M - $600M CAEL - 101 mAb 11 - 1F4 Amyloid light chain amyloidosis Initiate pivotal Phase 3 program 2H 2020 43% Caelum*** BAER - 101 α2/3 – subtype - GABA A PAM CNS Disorders Preclinical POC data to support IND in Refractory Epilepsy anticipated 2020 67% Baergic 4.5% Royalty ~$200M - $300M (refractory epilepsy) Near - term Value Creating Pipeline Registration - enabling † Estimated as of 6.26.2020 *Includes product candidates in development at Fortress, at its majority - owned and majority - controlled partners and at entities in which it holds minority ownership positions. **FBIO is eligible to receive ~29% of the proceeds upon the second - stage closing of the InvaGen transaction net of fees, and currently owns 23% of Avenue’s issued and outstanding capital stock. ***FBIO is eligible to receive ~43% of the proceeds from an Alexion acquisition option exercise, and currently owns ~40% of C ael um’s issued and outstanding capital stock. ****FBIO receives ~1/3 of the CVR Royalty on gross profits based on certain net sales thresholds ^ Based on most recent internal forecasts and assuming approval in all denoted indications 14

Candidate* Indication Preclinical Phase 1 Phase 2 Phase 3 Next Milestone Partnership % / Royalty † MB - 102 AML, BPDCN, and hrMDS First patient expected to be treated in Mustang IND trial 3Q 2020 25% Mustang; 4.5% Royalty $500M - $700M CEVA - 101 Traumatic Brain Injury (pediatric and adult) Phase 2 Data in Peds expected 2H 2020 Phase 2 Data in Adults expected 2022 78% Cellvation; 4.5% Royalty $1B+ in US / EU MB - 101 Glioblastoma (GBM) COH expected to file IND for Phase 1 combination trial with MB - 108 4Q2020 25% Mustang; 4.5% Royalty $500M - $700M MB - 106 B - Cell Non - Hodgkin Lymphoma, and CLL First data disclosure from FHCRC Phase 1 trial expected 4Q2020 25% Mustang; 4.5% Royalty $750M - $1,000M MB - 103 GBM and Metastatic Breast Cancer to Brain First data disclosure from COH Phase 1 trials expected in 2021 25% Mustang; 4.5% Royalty $400M - $500M MB - 108 Glioblastoma (GBM) COH expected to file IND for Phase 1 combination trial with MB - 101 4Q2020 25% Mustang; 4.5% Royalty $200M (used only with MB - 101) MB - 104 Multiple Myeloma (MM) First data disclosure from COH Phase 1 trial expected 2021 25% Mustang; 4.5% Royalty $500M - $700M MB - 105 Prostate & Pancreatic Cancers First data disclosure from COH Phase 1 prostate cancer trial expected 1Q 2021 25% Mustang; 4.5% Royalty $500M - $700M Triplex Cytomegalovirus (CMV) Initiate Phase 2 study in kidney transplant 81% Helocyte; 4.5% Royalty $500M+ in US / EU Early Clinical Pipeline 15 † Estimated as of 6.26 . 2020 *Includes product candidates in development at Fortress, at its majority - owned and majority - controlled partners and at entities in which it holds minority ownership positions. ^ Based on most recent internal forecasts and assuming approval in all denoted indications Potential Peak Sales Revenue^

Candidate* Indication Preclinical Phase 1 Phase 2 Phase 3 Next Milestone Partnership % / Royalty † Potential Peak Sales Revenue^ ATVS - 001 Gene Therapy AMD, PNH, and aHUS Non - human primate long - term toxicology data and additional POC in Dry AMD 62% Aevitas; 4.5% Royalty >$1B AAV - ATP7A Gene Therapy Menkes Disease Nominate candidate for clinical development in 2021 79% Cyprium; 4.5% Royalty ~$100M - $400M CEVA - 102 Traumatic Brain Injury (TBI) Initiate Phase 1 Study in 2021 78% Cellvation; 4.5% Royalty $1B+ in US / EU ConVax Cytomegalovirus Prevention & Control Initiate Phase 1 Study in 2021 81% Helocyte; 4.5% Royalty $1B+ in US / EU ONCOlogues KRAS G12D Finalize KRAS G12D in - vivo dataset 80% Oncogenuity; 4.5% Royalty >$10B ONCOlogues Other Genetically Driven Cancers & Coronaviruses POC in genetic disorders (non - oncology) and coronaviruses 80% Oncogenuity; 4.5% Royalty Multiple >$1B opportunities Pre - Clinical Pipeline 16 † Estimated as of 6.26.2020 *Includes product candidates in development at Fortress, at its majority - owned and majority - controlled partners and at entities in which it holds minority ownership positions. ^ Based on most recent internal forecasts and assuming approval in all denoted indications

17 Potential Near - term Value - Creating Events for FBIO Shareholders 1 IV Tramadol, CAEL - 101, Cosibelimab, CK - 101, CUTX - 101, MB - 107 (newly diagnosed XSCID), MB - 207 (previously transplanted XSCID) an d ONCOlogues are product candidates in development at FBIO partner companies 2 Fortress to receive ~1/3 of CVR royalty if certain net sales thresholds are met IV Tramadol 1 & Cipla o FBIO eligible to receive up to $48M upfront in contingent acquisition of Avenue o CVR Payout of 10 - 20% of gross profits 2 o PDUFA goal action date of 10/10/2020 MB - 107 & MB - 207 1 o Expect to commence Phase 2 registration trial for newborns with XSCID shortly o File IND for Phase 2 registration trial in previously transplanted patients, expected Q4 2020 Journey Medical o Generated $34.9M in net revenue for the full year 2019; a 49% increase over 2018 o Generated $21.4M in revenue in the first half of 2020, a 50% increase over the first half of 2019 o Expect to acquire 1 to 2 new revenue - generating dermatology products in 2020 Cosibelimab and CK - 101 1 o Interim data update for cosibelimab expected in 2H 2020; Complete enrollment in cosibelimab registration - enabling CSCC expansion cohort expected year - end 2020 o Potential initiation of CK - 101 global registration study for treatment of lung cancer ONCOlogues Platform o KRAS G12D pre - IND completion PRVs (Priority Review Vouchers) o Filing for at least 2 PRVs anticipated (CUTX - 101, MB - 107 (newly diagnosed) and MB - 207 (previously transplanted)) 1 o Data suggests PRVs may be worth ~$75M to ~$110M, each CAEL - 101 1 & Alexion o Eligible to receive 43% of up to $500M (upfront and approval / sales milestones) in event of Alexion exercise of contingent option o Initiate pivotal Phase 3 program in 2H20

18 o Lentiviral vector gene therapy o ~1 in 225k newborns per year (U.S.) o ~400 patients living with XSCID post - transplant in the US and ~650 patients living with XSCID post - transplant in high and mid - income ex - U.S. countries o RMAT Designation for MB - 107 granted by FDA in August 2019; Rare Pediatric Disease Designation for MB - 107 granted by FDA in August 2020 o Published clinical results demonstrate**: o Multilineage engraftment of transduced cells o Reconstitution of functional T cells and B cells o Normalization of NK - cell counts MB - 107 & MB - 207* Fortress Biotech Near - Term Value Creating Pipeline Assets XSCID “Bubble Boy” Disease Est. Market $200M / year Status Phase 2 Next Steps File IND for Phase 2 registration trial in previously transplanted patients, Q4 2020 (new designation – MB - 207) PRVs PRVs for each of the 2 patient populations, ~$75M to ~$110M for each PRV *Product candidates in development at Mustang Bio, Inc., an entity which was founded by Fortress and in which Fortress still mai ntains a large ownership position. ** Mamcarz E et al. N Engl J Med. 2019; 380: 1525 - 1534; also, Mamcarz E et al. Blood. 2019;134(Suppl1): 2058.

19 o FDA granted Rare Pediatric Disease, Orphan Drug and Fast Track designations o EMA granted Orphan Medicinal Product Designation o Would be the first FDA approved therapy in this indication o Eligible for Rare Pediatric Disease Priority Review Voucher (valuation range ~$75M to $110M) CUTX - 101 Fortress Biotech Near - Term Value Creating Pipeline Assets Menkes Disease Est. Market Estimated Peak Sales of $175M Status Phase 3 enrollment complete Next Steps Rolling NDA submission expected to start in 4Q 2020 and be completed in 1H 2021 PRV Eligible for PRV ~$75M to ~$110M

20 o Fully human IgG1 monoclonal antibody o Potential therapy for lung cancer, endometrial cancer, colorectal cancer and cutaneous squamous cell carcinoma o Potentially differentiated vs marketed PD - (L)1s o Interim P1 data showed efficacy in multiple tumor types w/ well tolerated safety profile o Enrolling cohorts intended to support potential BLA submissions o Exploring possible partnerships and collaborations COSIBELIMAB* Fortress Biotech Near - Term Value Creating Pipeline Assets Anti - PD - L1 Est. Market PD - L1 mAbs : $40b+ / year Status Registration - enabling Phase 1 Next Data Anticipated 2H 2020 Next Steps Complete enrollment in 2021 *Product candidate in development at Checkpoint Therapeutics, Inc., an entity which was founded by Fortress and in which Fortress still maintains a large ownership position.

21 o Irreversible inhibitor against selective mutations of EGFR o Potential to be effective in NSCLC patients with susceptible mutations as a monotherapy or in combination with anti - tumor immune potentiating therapies o Interim P1 data presented at 2018 World Conference on Lung Cancer o Potential emerging safety differentiation vs TAGRISSO ® CK - 101* Fortress Biotech Near - Term Value Creating Pipeline Assets Third - Gen EGFR Inhibitor *Product candidate in development at Checkpoint Therapeutics, Inc., an entity which was founded by Fortress and in which Fortress still maintains a large ownership position. Est. Market $6b+ / year Status Phase 1 Next Steps Initiate registration trial

Est. Market Estimated Peak Sales of $790M** Status FDA accepted NDA submission for review Next Steps PDUFA action date of October 10, 2020 CVRs Worth 10 - 20% of gross profits*** 22 o Uniquely positioned to address need for new post - operative pain therapies amid opioid crisis o Potential to replace conventional narcotics in wide range of patients o Two - stage acquisition agreement with Cipla minimizes dilution and provides substantial upside to shareholders; First stage closed in February 2019 o Strong IP position on proprietary dosing regimen expected to protect exclusivity in the U.S. until 2036 IV Tramadol* Fortress Biotech Near - Term Value Creating Pipeline Assets Post - operative pain management *Product candidate in development at Avenue Therapeutics, Inc., an entity which was founded by Fortress and in which Fortress st ill maintains a large minority ownership position **Based on internal forecasts ***Fortress to receive ~1/3 of CVR royalty if certain net sales thresholds are met

23 o Granted Orphan Drug designations in the U.S. and EU o No FDA, EMEA, or PMDA approved therapies in this indication o ~30k - 45k patients in U.S. and EU o ~4.5k newly - diagnosed patients (U.S.) per year o Potentially understated market size given AL Amyloidosis often misdiagnosed CAEL - 101* Fortress Biotech Near - Term Value Creating Pipeline Assets AL Amyloidosis *Product candidate in development at Caelum Biosciences, Inc., an entity which was founded by Fortress and in which Fortress still maintains a large minority ownership position. Est. Patient Population 30k to 45k patients in U.S. and EU Status Phase 2 Next Data Phase 2 safety data readout anticipated 3Q 2020 Next Steps Phase 3 study initiation 2H 2020

24 o Delivery platform allows PNAs to enter cell membrane & nucleus, displacing mutant DNA strand, preventing mutant mRNA transcription o ONCOlogues work higher upstream than traditional antisense and small molecule approaches, targeting the root of genetic disease o KRAS G12D remains a complete unmet need and plays a heavy role in devastating cancers, including: ~35% of pancreatic, ~12% of colorectal, and ~5% of endometrial and NSCLC o KRAS G12C for NSCLC is considered ~$4B market opportunity with ~40K patients in the US/EU o KRAS G12D has ~180K patients in the US/EU within pancreatic, colorectal, endometrial and NSCLC o Single Stranded RNA viruses, like COVID - 19, are easily targeted by ONCOlogues ONCOlogues* Fortress Biotech Near - Term Value Creating Pipeline Assets Gene - Silencing at the DNA Level Est. Market Various Gene - Silencing Markets >$1B each KRAS G12D estimated >$10B Status Pre - Clinical Next Steps Finalize KRAS G12D in - vivo dataset POC in genetic disorders (non - oncology) POC in coronaviruses Additional Oncogene targets Finalize clinical formulation *Product candidates in development at Oncogenuity, Inc., an entity which was founded by Fortress and in which Fortress still mai ntains a large ownership position.

25 o High affinity, selective modulator of GABA α receptor system o Selective positive allosteric modulator (PAM) for GABAα2/3, minimizing adverse events that are typically seen with benzodiazepines, which are non - selective agonists o Established safety profile o Epilepsy is among the most prevalent neurological disorders, affecting ~1% of the world population (~3M in the U.S.) BAER - 101 Fortress Biotech Near - Term Value Creating Pipeline Assets CNS Disorders Est. Patient Population ~1M refractory epilepsy patients per year in U.S. Status Phase 1 in CNS Disorders Next Steps Finalization of pre - clinical proof - of - concept data for BAER - 101 to support IND in Refractory Epilepsy anticipated 2020 *Product candidates in development at Baergic Bio, Inc., an entity which was founded by Fortress and in which Fortress still mai ntains a large ownership position.

26 Key Takeaways ONE TWO THREE FOUR Valuation Dislocation Near - term Key Catalysts that will Create Value Opportunities Robust Pipeline with 25+ Development - stage Biotech Product Candidates 1 Solid Track Record of Execution FIVE Near - term Revenue Growth 1 Includes employees and product candidates in development at Fortress, at its majority - owned and majority - controlled partners.

NASDAQ FBIO Shares outstanding as of 6/30/20: 86,113,331 Market Cap as of 8/17/20: ~$279.0 million Consolidated cash as of 6/30/20: $199.9 million 1 FBIO standalone cash as of 6/30/20: $86.3 million 2 Value of FBIO ownership of public partner companies as of 8/17/20: ~$109.1 million 3 1 C onsolidated cash, cash equivalents, short - term investments (certificates of deposit) and restricted cash 2 Fortress’ cash, cash equivalents, short - term investments (certificates of deposit) and restricted cash (excludes public partner companies) 3 Approximate value of Fortress’ holdings in ATXI, CKPT and MBIO FORTRESS BIOTECH Financial Snapshot 27

Investment Highlights 28 o World class management team with extensive experience in all facets of biotech with multiple successful exits ; o Implementing revenue generating model focusing on low risk and low cost portfolio acquisition using strategic partners for funding ; o Deep existing portfolio with multiple opportunities for cash generation, well in excess of preferred dividend .